As millions await approved therapies, myTomorrows strengthens its global patient-access mission with €25 million

myTomorrows, a Dutch HealthTech company that connects patients with possible pre-approval treatments, today announced the close of a €25 million financing in order to accelerate the global expansion of its AI-driven platform and enhance access to emerging therapies for patients worldwide.

Avego’s growth equity investment will fuel the global expansion of myTomorrows’ integrated pharma solutions to make emerging treatments more equitable and accessible for patients globally.

“This investment marks a pivotal step in our journey to give every patient, no matter where they live, a fair shot at tomorrow’s therapies,” said Michel van Harten, CEO of myTomorrows. “Avego’s extensive expertise in life sciences, particularly BioPharma, will be instrumental as we scale our platform and broaden our impact across the global health landscape.”

This growth-equity investment in myTomorrows aligns with several notable 2025 European HealthTech funding rounds.

In Belgium, Sequana Medical secured €24 million to support the US launch of its “alfapump” device for chronic fluid-retention management. In France, ArcaScience raised €6 million to enhance AI-driven benefit-risk intelligence for drug development. Meanwhile, Finland’s CurifyLabs obtained €6.7 million to modernise the production of personalised medicines.

While these companies operate in adjacent segments of the broader HealthTech and BioPharma landscape, myTomorrows stands out for its focus on patient access to pre-approval therapies through an AI-enabled platform that connects physicians, trial sites, and biopharma partners.

Its round represents one of the more substantial Dutch HealthTech financings reported in 2025, underlining continued investor confidence in technology solutions that bridge early-stage drug development and patient access.

Ronald Brus, Founder and Board Member of myTomorrows, added: “When we founded myTomorrows in 2012, we envisioned a better way to connect patients with promising therapies – one that complements drug development and expands access to innovation. This investment marks the beginning of a next phase of accelerated growth and worldwide impact.”

Founded in 2012, myTomorrows is a global HealthTech company that connects patients, physicians, trial sites, and BioPharma partners to enable earlier and better access to pre-approval treatments.

Through a centralised, multi-stakeholder platform, myTomorrows combines AI-driven insights with human expertise to deliver tailored solutions that aim to overcome some of today’s greatest barriers to patient access.

Headquartered in Amsterdam, with an office in New York City, myTomorrows has supported more than 16,900 patients and 2,800 physicians across 340+ sites in over 133 countries.

With more than 300 million patients worldwide facing conditions without approved treatment options, and over 10,000 therapies currently in development or awaiting approval – myTomorrows is addressing one of healthcare’s most urgent challenges: bridging the gap between scientific advancement and patient access to pre-approval treatments, which include clinical trials and expanded access programs (EAPs).

The new investment will accelerate myTomorrows’ international growth and further develop its AI-driven global platform that connects physicians and their patients, trial sites and BioPharma partners to streamline access and insight.

It will also strengthen collaborations with industry partners to shorten clinical development timelines and enhance real-world data capabilities, supporting evidence generation and regulatory insight.

“Avego is proud to support myTomorrows in its mission to transform how patients and physicians access therapies in development,” said James Flexner, Managing Partner at Avego. “We believe myTomorrows is uniquely positioned to remove barriers for patients and providers while serving as an essential partner to BioPharma.”

For BioPharma partners, myTomorrows provides clinical trial recruitment, expanded access solutions, and real-world data collection. For trial sites, the platform offers a unified referral management system that enhances trial visibility and enables real-time status updates.

EU-Startups has featured myTomorrows multiple times – first in 2017, reporting on its €10 million funding round, and later in its 2021 roundup of top healthcare startups in the Netherlands.

The post As millions await approved therapies, myTomorrows strengthens its global patient-access mission with €25 million appeared first on EU-Startups.